



Kubota Vision Announces Issuance of Patent Covering Kubota Glass Technology

Seattle (November 20, 2024) — Kubota Vision Inc. (“Kubota Vision” or the “Company”), a clinical-stage specialty ophthalmology company and a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), today announced the issuance of a patent covering Kubota Glass technology from the U.S. Patent and Trademark Office, assigned to the Company, adding strength to the Company’s intellectual property position.

The patent obtained this time is related to the technology for integrating a flexible PCB into a soft contact lens, a method for which was patented on August 9, 2022 (Patent No. 11,409,136). The flexible PCB is a type of base commonly used in computer hinges, known for its flexibility and lightweight properties. The Company holds a patent for this technology and its manufacturing method, which focuses on implementing the flexible PCB into a soft contact lens rather than a hard contact lens.

Title of the invention: SUPPORTING PILLARS FOR ENCAPSULATING A FLEXIBLE PCB WITHIN SOFT HYDROGEL CONTACT LENS

Abstract: A contact lens may include a body of contact lens material extending between a first surface and a second surface. An electromechanical component may be supported in the contact lens material between the first surface and the second surface. A support comprising a plurality of pillars may be formed of the contact lens material and may extend from at least one of the first surface and the second surface to the electromechanical component.

Issuance country: United States of America

Patent number: US 12,147,092

Date of Patent: November 19, 2024

Assignee: Acucela Inc.

About Kubota Glass™ Technology

Kubota Glass technology works to aid vision in myopia by projecting specially focused images generated using micro-LEDs in the peripheral visual field. The Company has been conducting and publishing research evaluating the device for the management of myopia. Kubota Glass technology leverages nanotechnology in its electronic glasses-based illumination device and seeks to help manage myopia by providing specially focused illumination while maintaining high-quality central vision.

About Kubota Vision Inc.

Kubota Vision Inc. is a wholly owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide. Kubota Pharmaceutical group’s pipeline includes a wearable device for myopia control using Kubota Glass technology and a handheld OCT device for the monitoring of neovascular retinal diseases, to be used directly by patients.

<https://www.kubotavision.com/>; <https://www.kubotaholdings.co.jp/en/>

Cautionary Statements

Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include statements regarding our expectations related to our development plans and ability to successfully develop and commercialize our product candidates and the potential efficacy, future development plans and commercial potential of our product candidates. These statements are based on current assumptions that involve risks, uncertainties and other factors that could cause the actual results, events or developments to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: our investigational product candidates may not demonstrate the expected safety and efficacy; our pre-clinical development efforts may not yield additional product candidates; any of our or our collaborators' product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; our clinical trials could be delayed; new developments in the intensely competitive ophthalmic pharmaceutical market may require changes in our clinical trial plans or limit the potential benefits of our investigational product candidates; the impact of expanded product development and clinical activities on operating expenses; adverse conditions in the general domestic and global economic markets; as well as the other risks identified in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. For a detailed discussion of the foregoing risks and other risk factors, please refer to our filings with the Securities and Exchange Commission, which are available on Kubota Pharmaceutical Holdings (Kubota Vision's parent company) investor relations website (<https://www.kubotaholdings.co.jp/en/ir/>) and on the SEC's website (<http://www.sec.gov>).

“Kubota Vision,” the Kubota Vision logo and “Kubota” are registered trademarks or trademarks of Kubota Vision Inc. or Kubota Pharmaceutical Holdings in various jurisdictions.

Media and Investor Relations Contact:

Press and Media Inquiries
Phone: +81-3-6550-8928
Email: pr@kubotaholdings.co.jp

###